Search
Search
Editorially independent content, supported with advertising
10.28.24
We finally have two FDA-approved treatments for geographic atrophy (GA)—and yet, many retina specialists have been reluctant to embrace them. Join moderator John Kitchens, MD, as he explores this question with Miguel Busquets, MD, and Esther Kim, MD. Further in the episode, they gameplan patient conversations centered around choosing a treatment, ask how heavily to weigh safety when selecting a complement inhibitor, and preview the GA pipeline.
12.12.24
GA Options in Clinical Therapy: Which Patients Are a Fit for GA Treatment?John Kitchens, MD; Saradha Chexal, MD; and Geeta Lalwani, MD
10.28.24
GA Options in Clinical Therapy: Why Aren't Doctors Embracing Complement Inhibition?John Kitchens, MD, Miguel Busquets, MD, and Esther Kim, MD
05.10.24
GA Options in Clinical Therapy, Part 1: Patient Selection and Treatment StrategiesDavid RP Almeida, MD, PhD, MBA; Lisa Faia, MD; and Chris Riemann, MD
05.10.24
GA Options in Clinical Therapy, Part 2: Real-World Cases in GADavid RP Almeida, MD, PhD, MBA; Lisa Faia, MD; and Chris Riemann, MD
